Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia
|ClinicalTrials.gov Identifier: NCT01139333|
Recruitment Status : Completed
First Posted : June 8, 2010
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying blood and tumor tissue samples from young patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: gene expression analysis Genetic: western blotting Other: flow cytometry Other: laboratory biomarker analysis|
- To evaluate Mer and Axl expression in samples from pediatric patients with acute myeloid leukemia (AML).
- To determine if abnormal expression of Mer and Axl is associated with poor clinical characteristics (e.g., induction failure or relapse) of AML in these patients.
OUTLINE: This is a multicenter study.
Archived samples from pediatric patients with acute myeloid leukemia are analyzed for Mer and Axl expression by flow cytometry and western blot assays.
|Study Type :||Observational|
|Estimated Enrollment :||52 participants|
|Official Title:||Evaluation of Mer and Axl Expression in Acute Myeloid Leukemia Patient Samples|
|Study Start Date :||September 2009|
|Primary Completion Date :||May 2016|
- Expression of Mer and Axl
- Association of abnormal expression of Mer and Axl with induction failure or relapse
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01139333
|Principal Investigator:||Kristen M. Eisenman, MD||University of Colorado, Denver|